logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Ipsen To Acquire Epizyme, Expanding Its Portfolio In Oncology

Jun 27, 2022•over 3 years ago

Acquiring Company

Ipsen SAS

Acquired Company

Epizyme

Boulogne-BillancourtManufacturingHealth Care

Description

Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients.

Company Information

Company

Ipsen SAS

Location

Boulogne-Billancourt, Ile De France, France

About

Ipsen SAS is a global biopharmaceutical group focused on innovation and specialty care. The company provides transformative medicines to patients worldwide, with a strong emphasis on oncology and rare diseases. Ipsen is listed on Euronext Paris and is known for its commitment to research and development.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed